phone Contact Us

Corporate Events

Opharmic Wins Gold Medal at the 50th International Exhibition of Inventions Geneva

Opharmic Wins Gold Medal at the 50th International Exhibition of Inventions Geneva

Geneva, Switzerland, Hong Kong, 14 April 2025

Opharmic Wins Gold Medal at the 50th International Exhibition of Inventions Geneva for MeticStim® Cell Stimulation Technology

Opharmic Technology (HK) Limited is proud to announce that it has been awarded a Gold Medal at the prestigious 50th International Exhibition of Inventions Geneva for its innovative cell stimulation technology under the MeticStim® platform. The award specifically recognizes the potential application of MeticStim® for optimizing CAR-T therapy, marking a major international validation of Opharmic's ultrasound-based medtech innovations.

The International Exhibition of Inventions Geneva is one of the world's largest and most respected invention competitions, attracting thousands of entries from inventors, researchers, and companies across the globe. Winning the Gold Medal in this competitive arena highlights the scientific novelty, technical excellence, and potential clinical impact of Opharmic's work.

MeticStim® is Opharmic's proprietary non-invasive ultrasound platform that delivers precise, controlled acoustic energy to modulate cellular behavior. In the context of CAR-T therapy optimization, MeticStim® is developed to potentially enhance the activation, proliferation, and functionality of chimeric antigen receptor T-cells without compromising their safety profile. This ultrasound-mediated approach aims to offer a non-invasive, tunable method to improve the efficacy of CAR-T therapies, which are revolutionizing cancer treatment but still face challenges such as manufacturing consistency, cell exhaustion, and limited persistence in vivo.

Throughout the decade, Opharmic has built a strong foundation in ultrasound transducer design, biological effect characterization, and translational research. The awarded technology builds upon the company’s broader expertise, including MeticTouch® for ocular drug delivery, demonstrating the versatility of its ultrasound platforms across multiple therapeutic areas.

"This Gold Medal is a tremendous honour and a powerful endorsement of our team's innovative approach," said Dr. Langston Suen, CEO of Opharmic Technology. "It validates years of dedicated research into non-invasive ultrasound cell stimulation and its potential to address key bottlenecks in advanced cell therapies like CAR-T. We are grateful to the jury and excited to continue pushing the boundaries of what ultrasound can achieve in medicine."

Opharmic’s team will continue to advance preclinical and translational studies, strengthen intellectual property protection, and explore strategic collaborations to accelerate the path from invention to clinical impact. The Geneva Gold Medal serves as both a celebration of past achievements and a catalyst for future growth.

This international accolade further strengthens Hong Kong's reputation as a hub for cutting-edge medtech innovation and underscores the global relevance of research originating from local institutions.

Author

Opharmic Technology